Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Shapiro

Showing results (201-210 of 205) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 205 results.
Cancer Cell|November 28, 2021
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancerLauren C Shapiro, Astha Thakkar, Sean T Campbell, et al.
Blood|September 24, 2024
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohortMendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, et al.
Haematologica|April 2, 2026
Treatment of <i>TP53</i>-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclaxMendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, et al.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2023
Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort StudyGayathri Nagaraj, Shaveta Vinayak, Ali Raza Khaki, et al.
Elife|October 17, 2023
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort studyGayathri Nagaraj, Shaveta Vinayak, Ali Raza Khaki, et al.
Pageof 21

Showing results (201-210 of 205) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 205 results.
Cancer Cell|November 28, 2021
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancerLauren C Shapiro, Astha Thakkar, Sean T Campbell, et al.
Blood|September 24, 2024
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohortMendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, et al.
Haematologica|April 2, 2026
Treatment of <i>TP53</i>-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclaxMendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, et al.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2023
Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort StudyGayathri Nagaraj, Shaveta Vinayak, Ali Raza Khaki, et al.
Elife|October 17, 2023
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort studyGayathri Nagaraj, Shaveta Vinayak, Ali Raza Khaki, et al.
Pageof 21